Safety, Tolerability, and Immunogenicity Study of Investigational Recombinant Botulinum Vaccine A/B (rBV A/B) in Volunteers Previously Immunized With Investigational Pentavalent Botulinum Toxoid

This study is enrolling participants by invitation only.
Sponsor:
Information provided by (Responsible Party):
California Department of Public Health
ClinicalTrials.gov Identifier:
NCT01701999
First received: October 3, 2012
Last updated: January 29, 2014
Last verified: January 2014
  Purpose

Study rBV A/B-CL-001 is a Phase 2b, 2-part, open-label, uncontrolled study to evaluate safety, tolerability, and immunogenicity of a single dose of recombinant botulinum vaccine A/B (rBV A/B) for the production of BabyBIG in volunteers previously immunized with the pentavalent botulinum (PBT) toxoid. This study is designed to determine neutralizing antibody levels for botulinum toxin types A and B in healthy subjects who were previously immunized with the PBT for occupational protection and who receive the rBV A/B. Subjects with titers of the neutralizing antibodies against the toxins would be candidates for plasma donation for BabyBIG production.


Condition Intervention Phase
Botulism
Biological: rBV A/B
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Official Title: Phase 2b, Two-part, Open-label, Uncontrolled Study to Evaluate Safety, Tolerability, and Immunogenicity of a Single 40-µg Dose of Recombinant Botulinum Vaccine A/B (rBV A/B) for the Production of BabyBIG® in Volunteers Previously Immunized With Pentavalent Botulinum Toxoid for Occupational Protection

Resource links provided by NLM:


Further study details as provided by California Department of Public Health:

Primary Outcome Measures:
  • Immunogenicity [ Time Frame: Baseline to 12 weeks ] [ Designated as safety issue: No ]
    The primary immunogenicity objective of this study is to evaluate the effects of a single dose of rBV A/B on the botulinum toxin types A and B neutralizing antibody concentration (NAC) over a 12-week period after receiving the rBV A/B vaccine in subjects who have previously been immunized with PBT for occupational protection.


Secondary Outcome Measures:
  • Frequency and Severity of Adverse Events [ Time Frame: Baseline to 12 weeks ] [ Designated as safety issue: Yes ]
    The primary safety objective of this study is to obtain safety information over a 12 week period on the use of rBV A/B in a population of plasma donors previously immunized with PBT for occupational protection with a long-term safety assessment (phone call follow-up) at 6 months. The frequency and severity of adverse events will be summarized by system organ class and preferred term.

  • Change in laboratory parameters from Baseline to 12 weeks [ Time Frame: Baseline to 12 weeks ] [ Designated as safety issue: Yes ]
    Changes in hematology, serum chemistry, and urinalysis parameters from baseline to the end of the study will be examined and summarized from baseline to week 12. Laboratory abnormalities will be assessed for relatedness. Treatment-emergent changes from normal to abnormal values in key laboratory parameters will be identified.


Estimated Enrollment: 83
Study Start Date: February 2013
Estimated Study Completion Date: December 2014
Estimated Primary Completion Date: September 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Vaccine Biological: rBV A/B
rBV A/B injections will consist of a single 40 µg injection of total antigen (20 µg of Antigen A and 20 µg of Antigen B) adsorbed to 0.2% (wt/vol) Alhydrogel™, in a total dose volume of 0.5 mL. The vaccine will be administered by intramuscular injection in the deltoid muscle, preferably in the nondominant arm.

  Eligibility

Ages Eligible for Study:   18 Years to 69 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • The volunteer has received pentavalent botulinum toxoid for occupational protection under BB IND 0161, with the previous pentavalent botulinum toxoid dose at least 6 months prior to the planned rBV A/B dose.
  • The volunteer is between the ages of 18 and 69 years at the time of consent.
  • The volunteer is healthy and has an acceptable medical history.
  • The volunteer meets the subject suitability requirements and recommendations for source plasma donors (for Part 2 subjects only).
  • The volunteer, if female and of childbearing potential, is not pregnant or lactating, and agrees to use an acceptable form of FDA-approved contraception for the duration of the study.
  • The volunteer has the ability to understand the requirements of the study and provide informed consent.
  • The volunteer agrees to complete the subject diary on a daily basis for 7 days post-vaccination and to report concomitant medication and adverse events during the study period.
  • The volunteer provides written authorization for use and disclosure of protected health information.
  • The volunteer agrees not to donate blood or blood products (outside of study procedures) during the course of the study.
  • The volunteer has personal health insurance.

Exclusion Criteria:

  • Be pregnant or nursing
  • The volunteer has a history of laboratory evidence of syphilis, acquired immunodeficiency syndrome, Creutzfeldt-Jakob disease, or infection with human immunodeficiency viruses 1 or 2, human T cell lymphotropic virus 1, hepatitis B virus, or hepatitis C virus.
  • The volunteer had prior severe local or severe systemic reaction to last immunization with pentavalent botulinum toxoid.
  • The volunteer has a known allergy to aluminum compounds, yeast, or other components of the vaccine.
  • The volunteer has donated one or more units of blood or undergone plasmapheresis within 28 days before screening.
  • The volunteer has received a blood product or immunoglobulin within 6 months of screening or plans to receive such products during the study.
  • The volunteer has received licensed nonliving vaccine within 14 days before study entry or licensed live vaccine within 60 days before study entry.
  • The volunteer has received investigational products (drugs, biologics, vaccines, or implantable devices) 60 days prior to study entry or plans to receive experimental products at any time during the study.
  • The volunteer has received prescription immunosuppressive or immunomodulatory agents, including parenteral, inhaled, or oral corticosteroids within 3 months before screening or plans on receiving such therapy at any time during the study with the exceptions (Subjects who have used prescription topical steroids may be enrolled 2 weeks after the therapy is completed; Intra-articular, bursal, or tendon injectable steroids are permitted; Any over-the-counter topical steroid use is permitted; Ophthalmic and intranasal steroids are permitted).
  • The volunteer has received cytotoxic therapy at any time in the previous 5 years to study entry.
  • The volunteer has an active systemic or recurrent disease that would place the subject at unacceptable risk of injury, require hospitalization, or require surgical intervention.
  • The volunteer has a history of alcohol or drug abuse within 12 months before screening.
  • The volunteer has past, present, or suspected illicit injection drug use.
  • The volunteer has inflammatory, vasculitic, or rheumatic disease, including systemic lupus erythematosus, polymyalgia rheumatica, rheumatoid arthritis, or scleroderma.
  • The volunteer has clinically recognized hepatic or renal insufficiency.
  • The volunteer has uncontrolled hypertension.
  • The volunteer has moderate to severe asthma, chronic obstructive pulmonary disease, or other significant pulmonary disease.
  • The volunteer has a seizure disorder.
  • The volunteer has moderate or severe illness or oral temperature of 100.4°F or greater within 3 days prior to immunization.
  • The volunteer is determined by the investigator to be unsuitable for participation in this trial for any reason.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01701999

Locations
United States, California
California Department of Public Health
Richmond, California, United States, 94804
Sponsors and Collaborators
California Department of Public Health
Investigators
Principal Investigator: Stephen S. Arnon, M.D. California Department of Public Health
  More Information

Additional Information:
No publications provided

Responsible Party: California Department of Public Health
ClinicalTrials.gov Identifier: NCT01701999     History of Changes
Other Study ID Numbers: rBV A/B-CL-001
Study First Received: October 3, 2012
Last Updated: January 29, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by California Department of Public Health:
Botulism Vaccine

Additional relevant MeSH terms:
Botulism
Clostridium Infections
Gram-Positive Bacterial Infections
Bacterial Infections
Neuromuscular Junction Diseases
Neuromuscular Diseases
Nervous System Diseases
Neurotoxicity Syndromes
Foodborne Diseases
Poisoning
Chemically-Induced Disorders

ClinicalTrials.gov processed this record on September 22, 2014